Study of the Prevalence of Iron Deficiency in Elderly Patient in Hospital Environment (CARENFERPA)
Iron deficiency is defined by insufficient tissue iron stores and anemia is the ultimate stage of iron deficiency. Anemia should never be neglected in an elderly subject because it is associated with an increase in mortality, but also with a increased morbidity in terms of complications
Apart from anemia, iron deficiency is common and constitutes a factor of poor prognosis in diseases chronic, all pathologies very frequently found in the elderly. It is the origin of the deterioration in the general condition of patients, their re-hospitalization or even the progression of their pathology.
In this context where elderly patients also present a certain number of comorbidities including the pathologies mentioned previously, it is important to better diagnose the deficiency martial in the elderly patient.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Iron deficiency (MD) is defined by insufficient tissue iron stores. Since iron is essential for the synthesis of hemoglobin, when the iron deficiency no longer makes it possible to maintain a sufficient level of erythropoiesis, anemia appears: it is the ultimate stage of iron deficiency.
Anemia is the most common haematological pathology encountered in geriatric practice. Its prevalence, in population generally ambulatory, is between 10 and 15% after the age of 65 and is greater than 20% beyond the age of 85.
Anemia should never be neglected in an elderly subject because it is associated with an increase in mortality, but also with a increased morbidity in terms of complications heart disease, cognitive decline, frailty, hospitalizations, and impairment of quality of life. About a third of anemias elderly person is attributable to a deficiency in vitamin B9 or B12 or an iron deficiency.
Apart from anemia, iron deficiency is common and constitutes a factor of poor prognosis in diseases chronic such as heart failure, kidney failure chronic or cancer, all pathologies very frequently found in the elderly. It is the origin of the deterioration in the general condition of patients, their re-hospitalization or even the progression of their pathology.
In this context where elderly patients also present a certain number of comorbidities including the pathologies mentioned previously, it is important to better diagnose the deficiency martial in the elderly patient.
This diagnosis is all the more important because, depending on the chronic pathology, data from the literature have shown that correcting the iron deficiency brings benefits to the patient by reducing the risk of recurrence of anemia, the prescription of erythropoietin and the use of transfusion for patients in oncology, gastroenterology and nephrology
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
ANGERS Cedex 9, France, 49933
- CHU Angers
-
Bayonne, France, 64100
- CH de Bayonne
-
Calais Cedex, France, 62107
- Ch de Calais
-
Chambéry, France, 73000
- CH Chambéry
-
Corbeil-Essonnes, France, 91100
- CHSF
-
Dunkerque Cedex 1, France, 59385
- CH de Dunkerque
-
Lille Cedex, France, 59037
- Hôpital Gériatrique Les Bateliers Chu Lille
-
Nantes Cedex 1, France, France
- Chu De Nantes, Hôpital Bellier
-
Nice, France, 6003
- CHU de NICE-hopital CIMIEZ
-
Paris Cedex 12, France, 75571
- Hopital Saint Antoine
-
Pau, France, 64000
- CH de Pau
-
Poitiers, France, 86021
- CHU de Poitiers
-
Strasbourg, France, 67000
- HUS - Hôpitaux Universitaires de Starsbourg
-
Tours Cedex 9, France, 37044
- Hôpital Bretonneau
-
Vandoeuvre-Lès-Nancy, France, 54511
- Chu Nancy
-
Villeurbanne, France, 69100
- HCL
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Any patient hospitalized in a geriatric unit (short geriatric stay, SSR) or seen on an outpatient basis (hospitalization day, consultation)
- Affiliated patient or beneficiary of a social healthcare system
- Patient having given written consent
Exclusion Criteria:
- Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by court order or administration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Blood sampling
|
Blood sampling
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of patients diagnosed with iron deficiency on inclusion
Time Frame: Day 1
|
The diagnosis of iron deficiency will be made from the measurements of the ferritinemia and CST: Ferritinemia < 100 µg/L and/or CST < 20%
|
Day 1
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-A00787-36
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.